Arcadia Biosciences (RKDA) Q4 2024 earnings summary

Executive summary

• 2024 marked the completion of a multi-year plan to focus on profitability, with a strategic exit from underperforming brands and a narrowed focus on Zola coconut water products.

• Zola coconut water revenues surged 124% in Q4 and 46% for the full year year-over-year, outpacing the coconut water category.

• Sale of GoodWheat assets and IP provided non-dilutive capital and reduced operating expenses, streamlining the business.

• Business combination agreement with Roosevelt Resources announced, expected to close in 2025.

• Leadership transition: Thomas J. Schaefer appointed CEO in July 2024.

Financial highlights

• Full year 2024 revenues were just over $5 million, up 13% year-over-year, with gross profit of $2.1 million and gross margins of 41.3%.

• Q4 2024 revenues reached $1.2 million, a 56% increase compared to Q4 2023, driven by a 124% increase in Zola sales.

• Full-year net loss attributable to common stockholders: $7.1M ($3.17/share) vs. $14.0M ($11.30/share) in 2023.

• Operating expenses for 2024: $8.7M, down 18% from $10.6M in 2023.

• Ended 2024 with $4.2 million in cash, down from $11.6 million at the start of the year.

Outlook and guidance

• Zola's expanded distribution in late 2024 is expected to drive further growth in 2025, with a healthy pipeline of new opportunities.

• Full benefit of new distribution gains will be realized over the entire 2025 year.

• Monetization of remaining wheat IP portfolio is targeted for the first half of 2025, likely through multiple transactions.

• Roosevelt Resources transaction expected to close by end of Q2 2025, reshaping ownership and business direction.